Home  |  Corporate Info  |  R & D  |  Products  |  Investor Relations  |  For the Patient  |  Careers at Hemispherx  


Officers and Directors
Officers and Directors Bios
Scientific Advisory Board
Hemispherx Biopharma Locations
Key Contacts
Alliances

 

Corporate Alliances

BIKEN

 

Biovail
Alliance: Canadian Licensing Partner – Ampligen® - CFS
A major Canadian pharmaceutical company involved in drug development, clinical testing and marketing program for all of Hemispherx’s drug portfolio in Canada.

Contact:
Rolf Reininghaus
2488 Dunwin Drive
Mississauga, Ontario
Canada L5L 1J9
Phone: 416-285-6400
Fax:     416-285-6499
Website: http://www.biovail.com

Celdex
Alliance: Immunoaugmentation of cancer vaccines

Chronix Biomedical
Alliance: CFS, Gulf War Syndrome, Hepatitis B & C
Hemispherx holds an equity position in Chronix, which is involved in research on Gulf war syndrome (GWS) and reshuffled genes. One third of GWS patients exhibit the symptoms of CFS as well as the 37-kDa marker. The management believes that a subset of the GWS patients share a common disease pathway as CFS. Both the companies are in discussion with the department of defense to explore the potential clinical benefits to the GWS victims. Hemispherx has the rights to any therapeutics and diagnostics developed by Chronix for CFS, Gulf War Syndrome and Herpes infections. Hemispherx's technology, derived from examination of CFS Patients, is applicable in a number of disease categories.

 

Hollister-Stier Laboratories LLC
Alliance:  Contract manufacturing of Hemispherx’s experimental drug, Ampligen®

The achievement of the initial objectives described in the Letter of intent (LOI), in combination with the Polymer production facility under construction in New Brunswick, N.J., will enable Hemispherx to manufacture the Active Pharmaceutical Ingredient (API) for approximately 10,000 doses of Ampligen® per week. Based on the LOI, Hollister-Stier Contract Manufacturing has agreed to fill the Ampligen® API from Hemispherx. Production for significantly larger quantities of product are planned thereafter.

 

National Institute of Infectious Diseases, Tokyo, Japan
Alliance:  Avian Influenza

Hemispherx has signed a research agreement with the National Institute of Infectious Diseases, in Tokyo, Japan. The collaboration, by Hideki Hasegawa, M.D., Ph.D., Chief of the Laboratory of Infectious Disease Pathology, will assess Hemispherx’ experimental therapeutic Ampligen® as an adjuvant to the Institution’s nasal flu vaccine.

In a recent published study in the Journal of Virology (March 2005, p. 2910-2919), Dr. Hasegawa and colleagues found that double-stranded RNA (dsRNA), such as Ampligen®, increases the effectiveness of the influenza vaccine by more than 300% and Ampligen® may also convey cross-protection ability against variant viruses (mutated strains of influenza virus).

New data from preclinical studies on dsRNA, including Ampligen® supports the role of dsRNA therapeutics in improving the efficacy of the present standards of care in both influenza prevention and treatment of acute disease.
Information contained on the Hemispherx website other than historical information, should be considered forward-looking and is subject to various risk factors and uncertainties. For instance, the strategies and operations of Hemispherx involve risks of competition, changing market conditions, changes in laws and regulations affecting these industries and numerous other factors discussed on the Hemispherx website and in the Company's filings with the Securities and Exchange Commission. Accordingly, actual results may differ materially from those in any forward-looking statements. Additionally, all the referenced investigational drugs and associated technologies of the company are experimental in nature and as such are not designated safe and effective by a regulatory authority for general use and are legally available only through clinical trials with the referenced disorders. The forward-looking statements represent the Company's judgement as of the date of this website. The Company disclaims, however, any intent or obligation to update these forward-looking statements.